Lakefront Biotherapeutics N.V.
$25.95
Mkt Cap 1.71B
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drug…
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
—
/100 Overall
Calculating score…
Running full analysis
Ready to value this company?
Run a full DCF model with Monte Carlo simulation.
Run DCF Valuation →
Run a full DCF model with Monte Carlo simulation.
Key Metrics
Loading full analysis…
REVENUE TTM
$1.21B
FCF TTM
-$361.1M
P/E RATIO
3.0x
Running full 6-factor analysis…